Study of AK112 in the Treatment of Advanced Gynecological Tumors

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 9, 2021

Primary Completion Date

May 10, 2024

Study Completion Date

May 10, 2024

Conditions

Gynecologic CancerCancer MetastaticOvarian NeoplasmsCervical NeoplasmEndometrial Neoplasms

Interventions

DRUG

AK112

AK112 infusion biweekly

Trial Locations (2)

Qilu Hospital of Shandong University, Qilu

Chongqing University Cancer Hospital, Chongqing